The results of hemoglobin A~1c~ (HbA~1c~) measurements are used to evaluate quality of glycemic control in individuals with diabetes mellitus ([@B1]). However, several studies have reported that HbA~1c~ levels may be significantly higher in non-Caucasian patients with diabetes for a given blood glucose (BG) range ([@B2]--[@B4]). It has become clear that HbA~1c~ levels not only depend on the long-term BG concentration ([@B5]--[@B7]) but also may be influenced by genetic factors ([@B8]--[@B10]) as well as environmental factors such as smoking and obesity ([@B11]).

The authors of the A1C-Derived Average Glucose study proposed to translate HbA~1c~ into estimated average glucose (AG) equivalents for monitoring glycemic control ([@B12]). They asserted that this could facilitate the patient's comprehension of the value of a given HbA~1c~ measurement and could be used instead of HbA~1c~. However, the potential racial and ethnic differences in hemoglobin glycation ([@B3]) and the impact of hemoglobin variants and erythrocyte survival on the HbA~1c~ assay ([@B13]) suggest that estimated AG may be a biased estimate of mean self-monitored BG (SMBG), depending on the specific ethnic group.

The aims of the current study were to analyze in the participants of the DURABLE trial the relationships between HbA~1c~ and mean SMBG across different ethnic groups with type 2 diabetes and to compare HbA~1c~-derived estimated AG with mean SMBG to determine whether estimated AG is an accurate measure of glycemia.

RESEARCH DESIGN AND METHODS {#s1}
===========================

The DURABLE trial (assessing the durability of basal vs. Lispro Mix 75/25 insulin efficacy) was a global study with the primary objective of comparing the efficacy, safety, and durability of two starter insulin regimens in patients with type 2 diabetes ([@B14]). It enrolled a large, diverse cohort of patients from five continents. The DURABLE trial was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. All sites received approval from Institutional Review Boards, and all patients provided written informed consent. Men and women 30 to 80 years of age with type 2 diabetes and HbA~1c~ \>7.0% (53 mmol/mol) with use of at least two oral BG--lowering agents (minimum dose 1,500 mg/day metformin, one-half maximum daily dose sulfonylurea, and/or either 30 mg/day pioglitazone or 4 mg/day rosiglitazone) for at least 90 days immediately before the study were eligible for the study ([@B14]). Patients were excluded if they had a history of long-term insulin therapy, BMI \>45 kg/m^2^, recent history of severe hypoglycemic episodes, or history of significant renal, hepatic, hematologic (including hemoglobinopathy, hemolytic anemia, sickle cell anemia, and severe blood loss), oncologic, or cardiac disease. Serum creatinine screening was performed locally for all patients. Metformin-treated patients were excluded if serum creatinine was ≥124 µmol/L (1.4 mg/dL) for women and ≥133 µmol/L (1.5 mg/dL) for men. At study entry, patients self-reported ethnic origin based on the following categories: Caucasian (European, Mediterranean, Middle Eastern), African descent (black), East/Southeast Asian (Myanmarese, Chinese, Japanese, Korean, Mongolian, Vietnamese), Western Asian (Pakistani, Indian Subcontinent), Hispanic (Mexican-American, Mexico, Central and South America), and other (mixed racial parentage, American Indian, Inuit). Because of the heterogeneity of their backgrounds, the small group of 62 individuals reported as \"other\" is not included in this analysis.

Measurements {#s2}
------------

Clinical measurements taken at baseline included HbA~1c~ (Bio-Rad Variant HbA~1c~ assay; Bio-Rad Laboratories, Hercules, CA) and fasting BG. HbA~1c~ was measured by Covance regional laboratories, which perform regular interregional quality control in accordance with National Glycohemoglobin Standardization Program Level I certification (Geneva, Switzerland \[European samples\], Sydney, Australia \[Australian samples\], Indianapolis, Indiana \[North and South American samples\], and Singapore \[Indian samples\]). In this assay, the reference range for HbA~1c~ was 4.3--6.1% (23--43 mmol/mol). Subjects were trained regarding how to monitor their own glucose levels using the glucose meters and how to complete the patient diaries. In the 2 weeks before the baseline visit, patients were instructed to record three 7-point SMBG profiles consisting of three premeal (first measurement required to be fasting) measurements, three 2-h postprandial measurements, and a measurement at 3:00 [a.m.]{.smallcaps} with a Roche Active or Roche Aviva BG meter (Roche Diabetes Care, Mannheim, Germany).

Calculations and analysis {#s3}
-------------------------

The mean SMBGs were calculated with an arithmetic mean based on the three 7-point BG profiles. The estimated AG was calculated by inserting observed HbA~1c~ into the A1C-Derived Average Glucose study linear regression equation (estimated AG \[mg/dL\] = \[28.7 × HbA~1c~ (%)\] − 46.7; *r* = 0.92) ([@B12]) and then by converting to mmol/L. A mean BG index that quantifies the difference between mean SMBG and estimated AG for an individual patient was calculated as follows: mean BG index \[mmol/L\] = estimated AG \[mmol/L\] − observed mean SMBG \[mmol/L\].

The baseline characteristics of the participants are presented as mean (SD). Means were compared between ethnic groups with ANOVA. East and West Asian groups were combined for racial/ethnic analyses. The Tukey honestly significant difference test was used to adjust for multiple comparisons. When variables were not normally distributed, medians were compared with nonparametric Kruskal-Wallis test. Fisher exact test was used to analyze categorical variables. Pearson correlation coefficient was used to determine the association between variables. A population linear regression equation was calculated for all ethnic subgroups using the individual mean SMBG values and HbA~1c~ at baseline for each participant. PASW Statistics (version 20; IBM, Armonk, NY) was used to perform all statistical analyses.

RESULTS {#s4}
=======

A total of 1,879 patients with 7-point SMBG profiles available at baseline were included in the present analysis. The mean age was 57 years; among the entire patient group, 52.4% were men, 66.0% were Caucasian, 16.2% were Asian, 12.0% were Hispanic and 5.8% were of African (black) descent. A comparison of baseline characteristics between ethnic groups is shown in [Table 1](#T1){ref-type="table"}. At baseline, the median duration of diabetes was 8.0 years, mean (SD) BMI was 31.7 kg/m^2^ (6.0 kg/m^2^) and mean HbA~1c~ was 9.0% (1.3) (75 \[SD, 14\] mmol/mol). Asian patients had significantly higher postprandial BG levels than Caucasians. Mean HbA~1c~ levels were significantly higher in Hispanic and Asian participants compared with Caucasians.

###### 

Baseline characteristics of the study population by ethnicity

![](2931tbl1)

[Figure 1](#F1){ref-type="fig"} depicts the relationship between HbA~1c~ and mean SMBG for all participants in the different ethnic groups and the corresponding regression equations and resulting regression lines for the ethnic groups. Differences between the ethnic groups are the largest in the clinically relevant HbA~1c~ range of 7.0--9.0% (53--75 mmol/mol). In this range, as depicted in [Table 2](#T2){ref-type="table"}, the level of HbA~1c~ is 0.2--0.5% (2--6 mmol/mol) higher in Asian, Hispanic, and African descent participants compared with Caucasian participants.

![*A--D*: The relationship between HbA~1c~ and mean SMBG in the Caucasian, Asian, Hispanic, and African descent ethnic groups. The regression equations are as follows: (*A*) Caucasian HbA~1c~ (%) = 0.27 × mean SMBG (mmol/L) + 5.66; (*B*) Asian HbA~1c~ (%) = 0.25 × mean SMBG (mmol/L) + 6.05; (*C*) Hispanic HbA~1c~ (%) = 0.28 × mean SMBG (mmol/L) + 5.92; and (*D*) African descent HbA~1c~ (%) = 0.26 × mean SMBG (mmol/L) + 6.17, where mean SMBG is the mean of the SMBG profiles.](2931fig1){#F1}

###### 

Comparison of HbA~1c~ values at different mean BG levels between the different ethnic groups

![](2931tbl2)

The estimated AG levels, calculated from HbA~1c~ levels, are given in [Table 1](#T1){ref-type="table"}. As expected from the HbA~1c~ values, estimated AG is significantly higher in Hispanic and Asians than in Caucasians. [Figure 2](#F2){ref-type="fig"} depicts the relationship between the estimated AG and the mean SMBG. When estimated AG is an accurate reflection of mean SMBG, we expect a 1:1 linear relationship, which apparently is not the case. When we plotted the relationship between mean SMBG and mean BG index, i.e., the difference between estimated AG and mean SMBG, we observed a clearly deviant pattern. With mean BG levels \<11.6 mmol/L (210 mg/dL), this difference is \>0, whereas at higher BG levels this difference becomes negative. These findings indicate that at lower levels of mean BG, estimated AG overestimates true BG levels; at levels \>11.6 mmol/L (210 mg/dL), estimated AG underestimates the true BG level. This pattern proved similar for all ethnic groups (data not shown).

![*A*: Relationship between the estimated AG and the mean SMBG values. The observed regression line (solid line) differs significantly from the expected regression line (dotted line). *B*: Relationship between the mean BG index (difference between estimated BG and measured BG) and the mean SMBG values. At mean SMBG levels of ≤11.6 mmol/L (210 mg/dL), estimated AG overestimates the actual average BG; at BG levels \>11.6 mmol/L (210 mg/dL), estimated AG underestimates the true BG levels.](2931fig2){#F2}

CONCLUSIONS {#s5}
===========

We report the association between glycemic measures in a large racially and ethnically diverse population of patients with type 2 diabetes. There is a clear difference in the relationship between HbA~1c~ and mean SMBG in different ethnic groups, with the highest HbA~1c~---for a given BG level---in Hispanic participants and in participants of Asian and African descent and the lowest HbA~1c~ in Caucasians. In the clinically relevant HbA~1c~ range of 7.0--9.0% (53--75 mmol/mol), non-Caucasian ethnic groups had a 0.2--0.5% higher HbA~1c~ compared with Caucasians. These results add to the growing literature describing higher HbA~1c~ levels in non-Caucasian populations for a similar degree of hyperglycemia. Although biological and analytical variations may contribute to this difference, it is unlikely that these variations explain all of the difference. We have assessed diurnal variation in HbA~1c~ when measured in five different samples obtained between 8:00 [a.m.]{.smallcaps} and 11:00 [p.m.]{.smallcaps} in patients with type 2 diabetes ([@B15]). The resulting HbA~1c~ values were nearly identical (median intra-individual variation 1.3%), indicating very low biological and analytical variations within an individual. Even when laboratories use multiple analyzers, the total analytic imprecision is low ([@B16]). This suggests that the HbA~1c~ difference of (absolute) 0.2% (2.2 mmol/mol) is clinically relevant.

Another important finding is the relationship between estimated AG, calculated on the basis of HbA~1c~ measurement ([@B12]), and the actual values of mean BG as derived from self-monitoring. In the A1C-Derived Average Glucose study report, estimated AG was calculated in 507 patients (\>80% Caucasians) by combining weighted results obtained during a 3-month period from at least 2 days of continuous glucose monitoring performed four times, with seven-point daily BG monitoring performed at least 3 days per week ([@B12]). Although there was a good correlation between HbA~1c~ and estimated AG (*R*^2^ of 0.84 for the whole group), visual inspection of this relationship shows that an HbA~1c~ of, for instance, 7% (53 mmol/mol) was associated with estimated AG varying between 7.0 mmol/L (127 mg/dL) and 11 mmol/L (200 mg/dL). In the current study, we observed a clear discrepancy between estimated AG and actually measured mean BG levels. With BG levels ≤11.6 mmol/L (210 mg/dL), estimated AG was higher than the actual average mean BG. When mean BG levels were \>11.6 mmol/L (210 mg/dL), estimated AG was significantly lower than the measured BG levels. Thus, estimated AG overestimated BG at lower glucose levels and underestimated mean BG at higher glucose levels. From these results, we conclude that calculation of estimated AG from HbA~1c~ with the current formula leads to inaccurate results.

HbA~1c~ levels are determined by several factors, as has been described in several recent articles. In addition to BG levels, age, sex, BMI, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, current smoking, and alcohol consumption are independent predictors of HbA~1c~ level ([@B11]). The data presented in this report confirm previous articles in which it was described that persons of African descent have higher HbA~1c~ levels than Caucasian persons across the full spectrum of BG levels ([@B17],[@B18]). Another study reported a 0.5% (6 mmol/mol) higher HbA~1c~ in Hispanics compared with Caucasians ([@B2]). The investigators concluded that these differences may be based on types of lifestyles, health care access and utilization, or socioeconomic factors, and also possibly on biological differences such as hemoglobin glycation or erythrocyte survival ([@B2]). However, there was insufficient data to compare HbA~1c~ levels stratified for glycemic control based on BG monitoring. Our present analyses clearly show a 0.32--0.41% (3--5 mmol/mol) absolute difference in HbA~1c~ between Hispanics and Caucasians for a given mean BG level ranging from 5.6 to 15.0 mmol/L (100--260 mg/dL; [Table 2](#T2){ref-type="table"}). This difference may be explained, in part, by genetic determinants. In the third National Health and Nutrition Examination Survey, it recently was shown that at many HbA~1c~ genetic loci there is substantial race--ethnic heterogeneity in risk allele frequencies ([@B19]). For the clinical situation, these results imply that goals for HbA~1c~ need to be different according to ethnic background, and also that cutoff values for establishing the presence of type 2 diabetes are different according to ethnic background. For example, it recently was demonstrated that retinopathy prevalence begins to increase at a lower HbA~1c~ level in those of African descent than in Caucasians ([@B18]). Thus, in studies in which intensive diabetes treatment has been applied, such as the ACCORD study, using the same HbA~1c~ as treatment target for people from different ethnic backgrounds may have created a higher risk of hypoglycemia for those of Asian, African, or Hispanic origin. In this respect, reassessment of the ACCORD study results ([@B20]) with special attention to the relationship between ethnic background and risk of hypoglycemia seems warranted. An interesting finding in this study was that compared with Caucasians, Asians had higher postprandial BG levels despite similar fasting and premeal BG levels. This finding may suggest that this postprandial increase is a specific feature of type 2 diabetes in Asians.

One limitation of our study is that the association of HbA~1c~ and BG has been based on a single HbA~1c~ determination and on mean BG levels assessed from only three 7-point SMBG profiles obtained within a period of 2 weeks. However, the DURABLE trial included patients with relatively stable glycemic control and also ensured that BG measurements could be compared among participants by using a single type of BG meter (Roche, Mannheim, Germany). It has been shown clearly that HbA~1c~ levels reflect average glycemia of the most recent 5 weeks ([@B21]). We have no data regarding the quality of BG self-monitoring by the participants, because many of the participants may have been taught this technique during the run-in phase of the DURABLE trial. However, clinical experience suggests that patients find these BG meters easy to understand and use. Finally, there is a large amount of scatter in the data (as depicted in [Fig. 1](#F1){ref-type="fig"}), possibly as a result of biological variation or experimental/analytical error. However, this scatter was rather similar to the results presented by McCarter et al. ([@B22]) in type 1 diabetic individuals. Greater numbers would have allowed for more detailed subanalyses.

We conclude that ethnicity has a strong influence on the relationship between HbA~1c~ and mean BG levels obtained by self-monitoring. This background needs to be taken into consideration when assessing HbA~1c~ levels as part of evaluation of (quality of) diabetes treatment and for setting glycemic targets. Moreover, at mean BG levels \<11.6 mmol/L (210 mg/dL), estimated AG overestimates the actual average BG; at levels \>11.6 mmol/L (210 mg/dL), estimated AG underestimates the true BG levels, which limits the use of estimated AG as an accurate marker of glycemia in clinical practice.
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